Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE plc’s Parsortix a “game-changer” for prostate cancer detection, says CEO

Andrew Newland, chief executive of specialist med-tech company ANGLE plc (LON:AGL), believes the company’s Parsortix liquid biopsy could be a “real game-changer” in the battle against prostate cancer.

Data from a Barts Cancer Institute study suggested that the Parsortix system can not only detect the disease, but can also identify how aggressive it is.

Although Newland believes Parsortix will need at least 18 months of further research, he says he’s well aware that “there’s a tremendous opportunity here commercially”.

 
Meet Allergy Therapeutics plc, Cello Group plc, Sphere Medical Holding PLC and ValiRx Plc at our event, London, 06 October 2016. Register here »
Juliet.jpg
Why Invest In ANGLE plc? Read More Here

Register here to be notified of future ANGLE plc articles
View full AGL profile

ANGLE plc Timeline

Newswire
July 27 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.